ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Lunan Pharmaceutical Group and Boehringer Ingelheim side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Lunan Pharmaceutical GroupBoehringer Ingelheim
studies on the registry392,305
open to participants now1961
phase 3 studies under way1028
reach primary completion within a year445
programswith a study of their own in two years2045+21 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseLunan Pharmaceutical GroupBoehringer Ingelheim
Phase 1

Lunan Pharmaceutical Group: 8 of its 20 programs at phase 1

  1. F182112phase 1
  2. LNF2007phase 1
  3. LNF2105phase 1
  4. Dronedaroneno phase
  5. Budesonideno phase

and 3 more — sign in to see them all

40%

Boehringer Ingelheim: 18 of its 45 programs at phase 1

  1. BI 3821001phase 1
  2. BI 3000202_low dosephase 1
  3. BI 3776528phase 1
  4. BI 3810944phase 1
  5. BI 3814916phase 1

and 13 more — sign in to see them all

40%
Phase 2

Lunan Pharmaceutical Group: 4 of its 20 programs at phase 2

  1. F182112+CD38phase 2
  2. mosapridephase 2
  3. Vonorasan fumarate injection1phase 2
  4. Vonorasan fumarate injection2phase 2
20%

Boehringer Ingelheim: 15 of its 45 programs at phase 2

  1. BI 3034701phase 2
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2
  3. BI 1584862phase 2
  4. BI 1815368phase 2
  5. BI 3000202phase 2

and 10 more — sign in to see them all

33%
Phase 3

Lunan Pharmaceutical Group: 8 of its 20 programs at phase 3

  1. rulonilimabphase 3
  2. Beclomethasonephase 3
  3. Cetirizinephase 3
  4. Diphenhydraminephase 3
  5. F027phase 3

and 3 more — sign in to see them all

40%

Boehringer Ingelheim: 9 of its 45 programs at phase 3

  1. obrixtamigphase 3
  2. survodutidephase 3
  3. nerandomilastphase 3
  4. verducatibphase 3
  5. zongertinibphase 3

and 4 more — sign in to see them all

20%
Approved, new studies00%

Boehringer Ingelheim: 3 of its 45 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Tenecteplaseapproved, new study
  3. Pramipexoleapproved, new study
7%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Lunan Pharmaceutical Group4 readouts · 1 phase 3·

Lunan Pharmaceutical Group, Dec ’26: 1 program whose next study reaches primary completion

  1. LNF2007phase 1 · Dec 0 · NCT06752447
·

Lunan Pharmaceutical Group, Feb ’27: 2 programs whose next study reaches primary completion

  1. Vonorasan fumarate injection1phase 2 · Feb 0 · NCT06783257
  2. Vonorasan fumarate injection2phase 2 · Feb 0 · NCT06783257
···

Lunan Pharmaceutical Group, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Isosorbidephase 3 · Jun 30 · NCT06765993
····
Boehringer Ingelheim20 readouts · 3 phase 3·

Boehringer Ingelheim, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. survodutidephase 3 · Dec 8 · NCT07768813
  2. zongertinibphase 3 · Dec 10 · NCT06151574
  3. empagliflozinapproved, new study · Dec 11 · NCT07845630
  4. vicadrostatphase 3 · Dec 11 · NCT07845630
  5. verducatibphase 3 · Dec 14 · NCT07781631

and 3 more — sign in to see them all

·

Boehringer Ingelheim, Feb ’27: 1 program whose next study reaches primary completion

  1. BI 3776528phase 1 · Feb 3 · NCT06745297

Boehringer Ingelheim, Mar ’27: 4 programs whose next study reaches primary completion

  1. BI 764524phase 2 · Mar 5 · NCT06321302
  2. ezabenlimabphase 3 · Mar 8 · NCT05846516
  3. BI 765423phase 2 · Mar 11 · NCT07036523
  4. BI 3812465phase 2 · Mar 23 · NCT07553429

Boehringer Ingelheim, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. nerandomilastphase 3 · Apr 15 · NCT06806592
·

Boehringer Ingelheim, Jun ’27: 1 program whose next study reaches primary completion

  1. BI 3821001phase 1 · Jun 22 · NCT07908004

Boehringer Ingelheim, Jul ’27: 2 programs whose next study reaches primary completion

  1. BI 3814916phase 1 · Jul 12 · NCT07486115
  2. BI 3032950phase 2 · Jul 30 · NCT06636656

Boehringer Ingelheim, Aug ’27: 2 programs whose next study reaches primary completion

  1. BI 3802876phase 2 · Aug 5 · NCT07325526
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2 · Aug 31 · NCT06806852
·

Boehringer Ingelheim, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Tenecteplaseapproved, new study · Oct 2 · NCT07361302
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Lunan Pharmaceutical Group

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Boehringer Ingelheim

New programs 3

  • BI 4015092phase 1 · first study · Nov 3
  • BI 3968621phase 1 · first study · Sep 25
  • pumitamigphase 2 · first study · Sep 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • BI 3810477phase 2 · Nov 3 · Idiopathic Pulmonary Fibrosis

Study stopped 0

None

Primary completion later 7

Where they overlap

Conditions where at least two of them have programs: 11 in all. A program counts in each condition its studies name most.

ConditionLunan Pharmaceutical GroupBoehringer Ingelheim
Small Cell Lung Carcinomaboth · compare here

Lunan Pharmaceutical Group in Small Cell Lung Carcinoma: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Small Cell Lung Carcinoma in search

Boehringer Ingelheim in Small Cell Lung Carcinoma: 5 programs

  1. obrixtamigphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2
  5. Zocilurtatug Pelitecanphase 2

Their studies: Boehringer Ingelheim’s studies of Small Cell Lung Carcinoma in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Lunan Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 1 program

  1. rulonilimabphase 3

Their studies: Lunan Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Boehringer Ingelheim in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. zongertinibphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 2both · compare here

Lunan Pharmaceutical Group in Diabetes Mellitus, Type 2: 2 programs

  1. F027phase 3
  2. Valsartanphase 3

Their studies: Lunan Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Boehringer Ingelheim in Diabetes Mellitus, Type 2: 3 programs

  1. survodutidephase 3
  2. vicadrostatphase 3
  3. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Type 2 in search

Colorectal Neoplasmsboth · compare here

Lunan Pharmaceutical Group in Colorectal Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Boehringer Ingelheim in Colorectal Neoplasms: 3 programs

  1. ezabenlimabphase 3
  2. pumitamigphase 2
  3. Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049phase 1

Their studies: Boehringer Ingelheim’s studies of Colorectal Neoplasms in search

Heart Failureboth · compare here

Lunan Pharmaceutical Group in Heart Failure: 2 programs

  1. Valsartanphase 3
  2. Dronedaroneno phase

Their studies: Lunan Pharmaceutical Group’s studies of Heart Failure in search

Boehringer Ingelheim in Heart Failure: 2 programs

  1. vicadrostatphase 3
  2. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Heart Failure in search

Breast Neoplasmsboth · compare here

Lunan Pharmaceutical Group in Breast Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Breast Neoplasms in search

Boehringer Ingelheim in Breast Neoplasms: 2 programs

  1. zongertinibphase 3
  2. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Breast Neoplasms in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

Lunan Pharmaceutical Group in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. Beclomethasonephase 3
  2. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Pulmonary Disease, Chronic Obstructive in search

Boehringer Ingelheim in Pulmonary Disease, Chronic Obstructive: 1 program

  1. verducatibphase 3

Their studies: Boehringer Ingelheim’s studies of Pulmonary Disease, Chronic Obstructive in search

Carcinoma, Hepatocellularboth · compare here

Lunan Pharmaceutical Group in Carcinoma, Hepatocellular: 1 program

  1. rulonilimabphase 3

Their studies: Lunan Pharmaceutical Group’s studies of Carcinoma, Hepatocellular in search

Boehringer Ingelheim in Carcinoma, Hepatocellular: 1 program

  1. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Hepatocellular in search

Colitis, Ulcerativeboth · compare here

Lunan Pharmaceutical Group in Colitis, Ulcerative: 1 program

  1. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Colitis, Ulcerative in search

Boehringer Ingelheim in Colitis, Ulcerative: 1 program

  1. BI 3032950phase 2

Their studies: Boehringer Ingelheim’s studies of Colitis, Ulcerative in search

Depressive Disorder, Majorboth · compare here

Lunan Pharmaceutical Group in Depressive Disorder, Major: 1 program

  1. Diphenhydraminephase 3

Their studies: Lunan Pharmaceutical Group’s studies of Depressive Disorder, Major in search

Boehringer Ingelheim in Depressive Disorder, Major: 1 program

  1. Pramipexoleapproved, new study

Their studies: Boehringer Ingelheim’s studies of Depressive Disorder, Major in search

Lupus Erythematosus, Systemicboth · compare here

Lunan Pharmaceutical Group in Lupus Erythematosus, Systemic: 1 program

  1. F182112phase 1

Their studies: Lunan Pharmaceutical Group’s studies of Lupus Erythematosus, Systemic in search

Boehringer Ingelheim in Lupus Erythematosus, Systemic: 1 program

  1. BI 3000202phase 2

Their studies: Boehringer Ingelheim’s studies of Lupus Erythematosus, Systemic in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetLunan Pharmaceutical GroupBoehringer Ingelheim
PDCD1rulonilimabruleezabenlimab
A target, or a pathogen for a vaccine, known for: Lunan Pharmaceutical Group 8 of 20 · Boehringer Ingelheim 24 of 45 programs (17 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Boehringer Ingelheim: 21).